Cargando…

Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas

Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Indirli, Rita, Ferrante, Emanuele, Sala, Elisa, Giavoli, Claudia, Mantovani, Giovanna, Arosio, Maura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355708/
https://www.ncbi.nlm.nih.gov/pubmed/31001736
http://dx.doi.org/10.1007/s12672-019-00363-4
_version_ 1785075155707363328
author Indirli, Rita
Ferrante, Emanuele
Sala, Elisa
Giavoli, Claudia
Mantovani, Giovanna
Arosio, Maura
author_facet Indirli, Rita
Ferrante, Emanuele
Sala, Elisa
Giavoli, Claudia
Mantovani, Giovanna
Arosio, Maura
author_sort Indirli, Rita
collection PubMed
description Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age.
format Online
Article
Text
id pubmed-10355708
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103557082023-07-21 Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas Indirli, Rita Ferrante, Emanuele Sala, Elisa Giavoli, Claudia Mantovani, Giovanna Arosio, Maura Horm Cancer Original Paper Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Sixty-two women with microprolactinoma treated with cabergoline for at least 1 year and followed for 2 years after drug withdrawal were retrospectively selected. Patients were divided into two groups: 48 patients stopped cabergoline before menopause (“PRE” group), while 14 after menopause (“POST” group). Recurrence was defined by prolactin levels above normal, confirmed on two occasions. Overall, 39/62 women relapsed. Patients who relapsed apparently had higher prolactin before withdrawal (median 216.2, range 21.2–464.3 mIU/L) compared with those in long-term remission (94.3, 29.7–402.8 mIU/L; p < 0.05), and the risk of recurrence seemed lower in POST women (4/14, 29%) than in PRE ones (35/48, 73%, p < 0.005, OR 0.149, 95% CI 0.040–0.558). However, none of the factors (prolactin before withdrawal, menopausal status, treatment duration, complete adenoma regression) showed a correlation with recurrence risk in multivariate analysis. The best strategy able to optimize CBG treatment and withdrawal’s outcomes is still to be defined in microprolactinomas. Postmenopausal status cannot reliably predict long-term remission, and follow-up is needed also in women of this age. Springer US 2019-04-18 /pmc/articles/PMC10355708/ /pubmed/31001736 http://dx.doi.org/10.1007/s12672-019-00363-4 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Indirli, Rita
Ferrante, Emanuele
Sala, Elisa
Giavoli, Claudia
Mantovani, Giovanna
Arosio, Maura
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title_full Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title_fullStr Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title_full_unstemmed Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title_short Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
title_sort cabergoline withdrawal before and after menopause: outcomes in microprolactinomas
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355708/
https://www.ncbi.nlm.nih.gov/pubmed/31001736
http://dx.doi.org/10.1007/s12672-019-00363-4
work_keys_str_mv AT indirlirita cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas
AT ferranteemanuele cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas
AT salaelisa cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas
AT giavoliclaudia cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas
AT mantovanigiovanna cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas
AT arosiomaura cabergolinewithdrawalbeforeandaftermenopauseoutcomesinmicroprolactinomas